Individualised medicine: why we need Bayesian dosing

被引:40
作者
Donagher, Joni [1 ]
Martin, Jennifer H. [2 ]
Barras, Michael A. [3 ,4 ]
机构
[1] Royal North Shore Hosp, Dept Pharm, Sydney, NSW, Australia
[2] Univ Newcastle, Discipline Clin Pharmacol, Sch Med & Publ Hlth, Newcastle, NSW, Australia
[3] Univ Queensland, Sch Pharm, Brisbane, Qld, Australia
[4] Princess Alexandra Hosp, Pharm Dept, Brisbane, Qld, Australia
关键词
individualised drug dosing; Bayesian; DRUG; GUIDELINES; TOBRAMYCIN;
D O I
10.1111/imj.13412
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Individualised drug dosing has been shown to improve patient outcomes and reduce adverse drug events. One method of individualised medicine is the Bayesian approach, which uses prior information about how the population responds to therapy, to inform clinicians about how a specific individual is responding to their current therapy. This information is then used to make changes to the dose. Studies using a Bayesian approach to adjust drug dosing have shown that clinicians are able to achieve a therapeutic range quicker than standard practice. If concentration is related to a pharmacodynamic end-point, this means that the drug will be more effective, and the side-effects will be minimised. Unfortunately, the software options to assist with Bayesian dosing in Australia are limited. The aims of this article are to demystify the concepts of Bayesian dosing, set the context of the Bayesian approach using reference to other dosing strategies and discuss its benefits over current dosing methods for a number of drugs. The article is targeted to medical and pharmacy clinicians, and there is a practical clinical case to demonstrate how this method could be used in everyday clinical practice.
引用
收藏
页码:593 / 600
页数:8
相关论文
共 26 条
  • [1] [Anonymous], 1997, J Am Coll Cardiol, V29, P1474
  • [2] [Anonymous], J CLIN TOXICOL
  • [3] [Anonymous], 2013, Australian Health Survey: Biomedical Results for Chronic Diseases, 201112
  • [4] Vancomycin therapeutics and monitoring: a contemporary approach
    Avent, M. L.
    Vaska, V. L.
    Rogers, B. A.
    Cheng, A. C.
    van Hal, S. J.
    Holmes, N. E.
    Howden, B. P.
    Paterson, D. L.
    [J]. INTERNAL MEDICINE JOURNAL, 2013, 43 (02) : 110 - 119
  • [5] Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity
    Avent, M. L.
    Rogers, B. A.
    Cheng, A. C.
    Paterson, D. L.
    [J]. INTERNAL MEDICINE JOURNAL, 2011, 41 (06) : 441 - 449
  • [6] Comparing 3 Methods of Monitoring Gentamicin Concentrations in Patients With Febrile Neutropenia
    Avent, Minyon L.
    Teoh, JunLu
    Lees, Judith
    Eckert, Kerena A.
    Kirkpatrick, Carl M.
    [J]. THERAPEUTIC DRUG MONITORING, 2011, 33 (05) : 592 - 601
  • [7] Individualized compared with conventional dosing of enoxaparin
    Barras, M. A.
    Duffull, S. B.
    Atherton, J. J.
    Green, B.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (06) : 882 - 888
  • [8] Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens
    Bleyzac, N
    Souillet, G
    Magron, P
    Janoly, A
    Martin, P
    Bertrand, Y
    Galambrun, C
    Dai, Q
    Maire, P
    Jelliffe, RW
    Aulagner, G
    [J]. BONE MARROW TRANSPLANTATION, 2001, 28 (08) : 743 - 751
  • [9] Charles B., 2014, AUST PRESCR, V37, P210, DOI [10.18773/austprescr.2014.078, DOI 10.18773/AUSTPRESCR.2014.078]
  • [10] Donagher J., 2015, THERAPEUTIC DRUG MON